Zhejiang Jiuzhou to Acquire Suzhou Unit of Novartis AG for CNY790 Million

Zhejiang Jiuzhou Pharmaceutical Co. (603456.SH) will acquire a unit of Novartis AG in eastern China for 790 million yuan (US$110.5 million).

Zhejiang Jiuzhou will buy all of Suzhou Novartis, with the exception of its technology and drug-development assets. Suzhou Novartis is a branch of the Swiss pharmaceutical giant, which manufactures, develops and sells its drugs in China.

The acquisition will help Zhejiang Jiuzhou cement its position as a strategic supplier to Novartis, support its business development in Europe and the U.S., and improve its drug development and manufacturing capacities in China, according to the company.

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.